Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Código da empresaSLNO
Nome da EmpresaSoleno Therapeutics Inc
Data de listagemOct 23, 2014
Fundado em1999
CEODr. Anish Bhatnagar, M.D.
Número de funcionários92
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 23
Endereço100 Marine Parkway, Suite 400
CidadeREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94065
Telefone16502138444
Sitehttps://soleno.life/
Código da empresaSLNO
Data de listagemOct 23, 2014
Fundado em1999
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados